# Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

> **NCT04684212** · NA · WITHDRAWN · sponsor: **Brian O'Neill MD**

## Conditions studied

- Atrial Fibrillation
- Left Atrial Appendage Thrombosis
- CVA

## Interventions

- **DEVICE:** LAmbre PlusTM Left Atrial Appendage Closure System
- **DRUG:** Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)

## Key facts

- **NCT ID:** NCT04684212
- **Lead sponsor:** Brian O'Neill MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-07-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of Funding
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684212, "Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04684212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*